Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12CMatthew L. Condakes(Bristol-Myers Squibb (Germany)), Michelle L. Stewart(Bristol-Myers Squibb (Germany))Nature CommunicationsJanuary 31, 202610.1038/s41467-026-69003-0Cited by 3SaveCiteExport RISWatch citationsRelated PapersDiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic Targets|Clinical Cancer Research|2016|68DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets|Unknown|2016|8Supplementary Figure 3 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic Targets|Unknown|2023|0Supplementary Figure 2 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic Targets|Unknown|2023|0Supplementary Figure 2 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic Targets|Unknown|2023|0